Explore the challenges and advancements in anti-EGFR antibody treatment for metastatic colorectal cancer. Discover how ...

Bigner, MD, PhD Faillot and coworkers [21] also performed a phase I study to evaluate whether a single IV injection could deliver an adequate amount of anti-EGFR monoclonal antibody (MAb 425 ...

They prevent the EGFR protein on mutated cells from triggering tyrosine kinase, an enzyme within cells that activates cell division and, thus, multiplies cancer cells. Rybrevant (amivantamab) is a ...

A new BLA for datopotamab deruxtecan aims for FDA accelerated approval to treat EGFR-mutated NSCLC based on data from ...

For patients with previously treated EGFR-mutated NSCLC, a new BLA has been submitted to the FDA seeking the accelerated ...

monoclonal antibodies, such as cetuximab and panitumumab, directed against the extracellular domain of EGFR, and tyrosine kinase inhibitors, like gefitinib and erlotinib, which block the kinase ...

Discover six bispecific antibody companies developing a two-in-one approach to delivering targeted therapeutics to patients.